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Abstract
Many psychiatric conditions and traits are associated with significant heritability. Genetic risk for psychiatric conditions
encompass rare variants, identified due to major effect, as well as common variants, the latter analyzed by association
analyses. We review guidelines for common variant association analyses, undertaking after assessing evidence of herit-
ability. We highlight the importance of: suitably large sample sizes; an experimental design that controls for ancestry;
careful data cleaning; correction for multiple testing; small P values for positive findings; assessment of effect size for
positive findings; and, inclusion of an independent replication sample. We also note the importance of a critical discus-
sion of any prior findings, biological follow-up where possible, and a means of accessing the raw data.
Introduction
Extensive evidence suggests that many psychiatric
conditions have a substantial genetic component. A long-
standing perspective in the field of psychiatric genetics is
that a significant proportion of risk arises from common
variants, including single nucleotide polymorphisms
(SNPs) (see a general review of common variants in
Iyengar and Elston, 2007 [1]). Genome-wide and candi-
date-gene association studies represent means of testing
for common variants contributing to risk. Genome-wide
studies take an unbiased (i.e., non-hypothesis-driven)
view of the genome but bring with them a heavy burden
in terms of correction for multiple testing. In contrast, in
the typical candidate-gene association study, genes are
selected based on their function and/or position (if there
is positional information from linkage, chromosomal
rearrangements or copy number variant studies) and as
such are hypothesis-driven. In both cases, the design,
execution, analysis and interpretation of the studies are
crucial. The current commentary will address some of
the relevant issues.
Ten years ago, Nature Genetics, recognizing the difficul-
ties in replicating candidate gene association findings in
complex conditions or phenotypes, published an editorial
[2] that proposed criteria for acceptance of such studies.
Their recommendations were summarized as follows:
“Ideally, they should have large sample sizes, small
P values, report associations that make biological sense
and alleles that affect the gene product in a physiologi-
cally meaningful way. In addition, they should contain
an initial study as well as an independent replication,
the association should be observed both in family
based and population-based studies, and the odds ratio
and/or attributable risk should be high” (pp. 1-2).
While these remain excellent guidelines, advances over
the course of the past decade are such that these guide-
lines need to be revisited. First and foremost, genotyping
has become much more efficient, widespread, and less
expensive. For this reason genome-wide association stu-
dies are more common. On the other hand, most
laboratories with access to clinical samples can now
carry out smaller (candidate gene) association studies.
Second, empirical data have dramatically re-enforced the
fundamental concerns that precipitated the Nature
Genetics editorial, i.e., that genetic association studies
have mostly (but not entirely) failed to replicate. Third,
for many conditions, samples are available through
international repositories. And, fourth, we have greater
understanding of sources of error in association studies,
as well as how to best address them.
The widespread availability of less expensive genotyp-
ing and the access to international DNA repositories
do not need further elaboration here, and in relation
to autism we would direct the reader to the NIMH
http://www.nimhgenetics.org/, AGRE http://www.agre.
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The empirical data showing just how extensive the pro-
blems are warrant brief review, as do some of the evol-
ving methods to address them.
A core concern
In 2002, Hirschhorn et al. [3] surveyed 600 positive
association studies in medical genetics broadly (i.e., not
just autism) and focused on 166 genes that had been
studied three or more times. One distressing conclusion
was that only 6 of these 166 were consistently replicated
(defined as a positive association in at least 75% of the
follow-up studies). The news was not all bad, because
well over half of the remaining initial, positive associa-
tions were replicated at least once. Some of the most
consistent findings include APOE in Alzheimer disease,
INS in type I diabetes, CCR5 in HIV infection, PRNP in
Creutfeldt-Jakob disease, CTLA4 in Graves’ disease, and
F5 in deep vein thrombosis.
In a follow-up analysis, 301 studies covering 25 differ-
ent associations were studied in greater detail [4].
Pooled analysis of the follow-up studies supported evi-
dence for association by meta-analysis in 8 out of the 25
associations indicating that there were very modest, but
likely real, effects in about a third of the initial, positive
reports. Two of these positive replications were in psy-
chiatric conditions (schizophrenia in both, a disease
with an estimated heritability of 70-85% [5]), and the
estimated effect sizes should be noted: 1.12 for DRD3
(with a 95% confidence interval of 1.02-1.23 with a fixed
effect model) and 1.07 for HTR2A (95% confidence
interval of 1.01-1.14). Most recent analyses of these (and
other) candidate genes in schizophrenia by meta-analysis
find less support, if any, for association [6,7]. In any
case, for genes positive by meta-analysis, odds ratios are
all almost universally below 1.5 and typically below 1.25.
These effect sizes are consistent with both those derived
from studies in model organisms (usually mice) and those
now arising from genome-wide studies (per-allele odds
ratios less than 1.5, http://www.genome.gov/gwastudies/)
[8]. Going into a genetic study with a realistic expectation
of likely effect size will go a long way towards addressing
limitations in many association analyses. Association stu-
dies in autism (with estimates of heritability above 90%,
[5]) are not immune to the problems with candidate gene
association studies. Out of more than 100 published asso-
ciation studies in autism and associated conditions, less
than 10 have been consistently replicated (see http://wren.
bcf.ku.edu/ and http://gene.sfari.org/).
Updating the recommendations
Given this failure to replicate, we feel it would be useful
to elaborate on the recommendations made a decade
ago, as follows:
“large sample sizes” - In light of the modest effect
sizes anticipated in any study in psychiatric genetics,
power becomes a serious concern. Investigators now
recognize that a genome-wide study requires sample
sizes on the order of several thousand cases and con-
trols or trios to ensure detection of some common var-
iants of modest effect, unless the circumstances are
exceptional. Candidate gene studies are not much differ-
ent, even if the significance level for P-value used for
the test is larger. For example, even for effects on the
high side of the allelic odds ratio (i.e., near 1.5), sample
sizes of 500 or more cases and controls or trios would
be required to have good power to reject the null
hypothesis - even if one of the genotyped and tested
variants is a risk variant. When the true odds ratio
approaches 1.1, the required sample size is roughly an
order of magnitude larger. Note, moreover, that these
kinds of power calculations ignore the prior probability
that any selected gene contains a risk variant. This prob-
ability is likely to be small, given the limited scope of
the study and the findings regarding replication
described earlier. Large sample sizes are warranted even
in the case of a replication study where the first study
gives a higher estimated effect size, as it is likely that
the estimated effect size from the primary study repre-
sents an overestimate (sometimes referred to as “winner
curse”).
“small P values” - While small P values remain impor-
tant (with small implying P much less than 0.05), a
focus on P values alone is inadequate. A consideration
of effect size is always required (see below), and identi-
cal P values in different studies “can have different
implications for the plausibility of a true association
depending on the factors that affect the power of the
test, such as the minor allele frequency (MAF) of the
SNP and the size of the study” [9]. An underpowered
test can produce a small P value that in fact provides lit-
tle evidence against the null hypothesis. This gets back
to avoiding under-powered tests while scrutinizing the
genotype results to remove poorly-performing SNPs and
SNPs with a low minor allele frequency.
Data cleaning needs to be both rigorous and reported.
In addition to removing markers with low minor allele
frequency, markers and samples with higher failure rates
need to be removed, as do markers that fail Hardy-
Weinberg testing or cluster poorly. Data should be ana-
lyzed for cryptic duplicates and Mendelian and sex
inconsistencies. Finally, some sense of genotype error
rates should be presented. Note that there is no “per-
fect” approach to data cleaning, and it is difficult to
determine a priori the impact of poor quality data. It
might have little noteworthy effect in a single data set,
yet the effect could be compounded when numerous
data sets are combined, such as by meta-analysis.
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Making raw data available for scrutiny and meta-analy-
sis, increasingly the norm in genome-wide studies and
in studies making use of public DNA repositories, is
therefore encouraged.
Correction for multiple testing. While the standard in
genome-wide studies, candidate gene studies often fail
to provide correction for multiple testing. Reporting a
nominal P value that is likely the result of chance is not
accepted in science as a whole and should not be a part
of psychiatric genetic research. With the advent of DNA
repositories it is becoming much harder to provide sam-
ple-wide correction, but certainly experiment-wide cor-
rection is to be expected. With software programs like
PLINK and UNPHASED now available for permutation
testing [10,11], running such corrections should become
the norm.
“report associations that make biological sense and
alleles that affect the gene product in a physiologically
meaningful way” - This remains an ideal but has a dif-
ferent interpretation in genome-wide studies. In gen-
ome-wide studies the hypothesis-independent approach
can lead to novel findings that do not make sense in the
current conceptualization of a condition or phenotype,
even if true. And for psychiatric conditions it is possible
to develop an ad hoc story based only on the fact that a
gene is expressed in the brain. So, the criterion of biolo-
gical plausibility is a bonus but not necessarily a require-
ment. Follow-up analyses (or an a priori focus) on
functional alleles can help to making biological sense of
the association data. That is, if a genetic finding gives
rise to a physiologically well-specified hypothesis that
can be tested beyond a genetic design, this constitutes
stronger converging evidence.
“they should contain an initial study as well as an
independent replication” - Including replications in the
same report is the sine qua non for a meaningful con-
clusion. With the advent of DNA repositories it has
become harder to conceive of a study of a common
categorical trait that cannot avail itself to a replication
sample. The emphasis here is on the word ‘indepen-
dent’, since a within-sample replication may not be suf-
ficient (as phenotyping or genotyping errors may be
common to both halves of a split sample).
In addition, if there are other studies of the same
locus in the literature, careful analysis of sample overlap
needs to be described to ensure the principle of inde-
pendence. Furthermore, the extent to which the study
being presented replicates the prior findings should be
discussed, and should address whether the same marker
(or a marker in linkage disequilibrium) is showing the
same effect in the same direction.
“the association should be observed both in family
based and population-based studies” - The require-
ment for a family-based cohort arose from the
potential for false-positive findings due to population
stratification. With the advent of methods that adjust
for ancestry, it is more relevant to expect the design to
control for ancestry by either a family-based design or
sufficient number of markers to estimate and adjust
for ancestry. In general, case-control studies should
include matching based on ancestry using standard
approaches [12-14]; and with the reduced cost of geno-
typing, this is now an expectation in all well-designed
studies.
“the odds ratio and/or attributable risk should be high”
- This criterion warrants some elaboration. Empirical
data indicate that for many conditions and phenotypes,
high odds ratios and high attributable risk is the excep-
tion, not the norm. It is for this reason that the field of
psychiatric genetics has moved to ever-increasing sam-
ple sizes. It is more appropriate to expect that, for a sui-
tably-powered study, some measure of effect size be
provided. The replication sample gives an opportunity
to estimate effect size, which is likely - due to winner’s
curse - to be much more accurate than such an estimate
from the discovery sample.
Summary
Many psychiatric conditions are associated with signifi-
cant heritability [5], and many psychology traits, used as
endophenotypes or intermediate phenotypes, have
appreciable heritability as well. While there is emerging
evidence that a proportion of risk for many psychiatric
conditions resides in rare variants of major effect, there
is also compelling evidence for common variants, most
recently from independently replicated findings from
genome-wide association studies in schizophrenia and
autism [15-18]. With the advent of large, publically
available samples and inexpensive genotyping, the guide-
lines proposed ten years ago are now a target that is
accessible to most laboratories. Advances in the past
decade have also led to improved approaches to supple-
ment these guidelines. Taken together, a well-designed
and executed association study should have the follow-
ing components:
• Evidence of heritability for the condition or trait
• Suitably large sample sizes, in the context of
expected effect sizes and power
• Standardized, careful data cleaning, described in
detail
• Correction for multiple testing
• Inclusion of an independent replication sample
• Experimental design that controls for ancestry by
either a family-based design or by the inclusion of a
sufficient number of markers to estimate and adjust
for ancestry
• Small P values for positive findings
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• Presentation of metrics of effect size for positive
findings
• A critical discussion of any prior findings
• Biological follow-up (either experimental or, mini-
mally, in discussion)
• A means of accessing the raw data
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